1999-098 – Mayo Clinic has patent rights broadly claiming PD-L1 antibodies along with other PD-L1 related fundamental patent claims.
2011-092 – T cells drive adaptive immune responses that can turn out pathogenic when directed against your own body tissues and organs causing autoimmune diseases. On the other hand, T cells are the main cellular component driving acute organ rejection after transplantation. Therefore different strategies to deplete/inactivate T cells have been pursued to treat patients either suffering from autoimmime... Read More
2011-042 – DNA Aptamers Promoting Remyelination in Neurodegenerative Disease Single-stranded DNA aptamers 40 nucleotides in length were selected for binding to mouse myelin and were evaluated for their ability to promote remyelination. This approach was based upon previous reports indicating that IgM antibodies are capable of promoting remyelination in animal models of multiple sclerosis. After... Read More
2008-144 – Antibiotics fail when pathogens acquire genes that confer resistance to these drugs. This invention proposes generating vaccines specifically against the gene products of antibiotic resistance genes. These vaccines have the potential to counterselect against drug-resistant pathogens or may be used as an adjuvent to enhance drug therapy with the antibiotic by depleting the resistance gene. The... Read More
2005-237 – A protein from the fungus alternaria which induces recruitment and activation of eosinophils.
2003-048 – Method to Optimize Antigen Expression When Culturing Cells for Cancer Vaccines The culture of cells for use in cancer vaccines or for use in the discovery of tumor antigens occurs in a standard oxygen pressure environment of about 20 kilopascals (kPa). Mayo Clinic researchers have discovered that culturing cancer cells in a low (2 kPa) or high (90kPa) oxygen pressure increases expression... Read More
2002-244 – Mayo has discovered a gene, PKHDL1, that shows significant homology to PKHD1 (the gene mutated in autosomal recessive polycystic kidney disease that was discovered at Mayo and for which a patent application is pending). The protein predicted to be encoded by PKHDL1, fibrocystin-L, is a large receptor-like protein that is highly expressed on T lymphocytes. The protein is postulated to be an... Read More
2002-226 – Our invention is the use biological, pharmacological or saccharide intervention, genetic modification or selection, for antagonist or modulation of Toll-like receptor 4 (TLR4) or other TLRs for the increase and/or maintenance of bone density, osteoporosis, Paget’s disease, or any disease or condition in which bone loss is a factor.
Modulation of Toll-like Receptor 4 Signaling, or Other TLRs for Treatment or Prevention of Obesity and Excess Fat
2002-225 – Our invention is the use biological, pharmacological or saccharide intervention, genetic modification or selection, for antagonist or modulation of Toll-like receptor 4 (TLR4) or other TLRs for the maintenance, or reduction of fat body mass, obesity or any related conditions or diseases where body fat is a contributing factor.
2000-080 – The treatment of neutrophil-associated pulmonary inflammation including chronic obstructive pulmonary disease (smoker’s bronchitis), chronic bronchitis, cystic fibrosis, alphal-antitrypsin deficiency, adult respiratory distress syndrome and idiopathic pulmonary fibrosis by lidocaine inhalation.